The Food and Drug Administration Safety and Innovation Act (FDASIA) goes to the Senate for a vote next week after passing by a large margin in the House June 20. The new user fee legislation will result in a number of changes at FDA including generic user fees. At the current pace, signature into law by the President is expected by the 1st or 2nd week of July 2012.
Medical Device Consulting NewsNewsPharmaceutical Consulting NewsRegulatory AffairsRegulatory UpdatesResearch & DevelopmentSubmissions
